Edison research upgrades MSB valuation:
Mesoblast's partner Teva has now listed the details of its pivotal Phase III study of MPCs, now coded as CEP-41750 (formerly Revascor), in congestive heart failure (CHF). The large, 1,730-patient trial should begin to recruit patients in the next few weeks and is projected to render final data in mid-2018. CHF is the most important of the seven different indications being pursued with the MPC platform and, with US$4bn peak sales potential, it represents the largest component in our valuation. We consider the move supports a higher probability of success (50% vs 40%), which boosts our rNPV to A$3.0bn (A$9.06/diluted share). - See more at: http://www.stockopedia.com/research/teva-starts-phase-iii-chf-study-81033/#sthash.Vlne2H3D.dpuf
chf update
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |